This article covers the pharmacology of melatonin, the dose-response relationship between melatonin quantity and biological effect, the specific risks of excessive dosing, and the evidence-based therapeutic doses for each use case. See also the Melatonin Dosage Calculator, the Chronotype Quiz, and the Sleep Debt Calculator.

In the United States, between 2000 and 2018, melatonin supplement use increased by 425% — rising from the least commonly used natural supplement to the most commonly used one. Over the same period, emergency room visits related to paediatric melatonin ingestion increased by 530% (Lelak et al., JAMA Pediatrics, 2022). Most adults who take melatonin take between 5 and 10 milligrams per dose. The effective chronobiotic dose — the amount needed to shift the circadian clock and improve sleep timing — is 0.3 to 0.5 milligrams.

The gap between those two numbers is not minor. It is 10 to 33 times the effective dose. Most people taking melatonin are not taking too little — they are taking an amount that is physiologically equivalent to flooding a system designed to operate on microdoses with a pharmacological concentration that produces sedation, receptor desensitisation, and potentially long-term suppression of the body's own melatonin production — without producing proportionally better sleep.

Understanding the pharmacology of melatonin — how it works, at what doses, through which receptors, and with what consequences at excess — is the foundation for using it correctly. This article provides that understanding, with specific dose guidance for every clinical use case and the evidence basis for each recommendation. The Melatonin Dosage Calculator translates this evidence into personalised dose and timing guidance for your specific situation.

---

How Much Melatonin Is Too Much Per Night: The Dose-Response Science

What Melatonin Actually Is — and Is Not

The most important conceptual correction for people who use melatonin: melatonin is not a sedative. It does not cause sleep directly. It does not increase sleep duration in most healthy adults. It does not deepen sleep stages or increase slow-wave or REM sleep.

Melatonin is a chronobiotic — a circadian timing signal. Secreted by the pineal gland starting approximately 2 hours before habitual sleep time, it communicates to the body's peripheral clocks that biological night has begun. Its primary biological actions are:

1. Phase shifting the circadian clock — melatonin taken at the correct time relative to the current circadian phase can advance or delay the clock
2. Marking the onset of biological night — coordinating the body's overnight hormonal and metabolic processes
3. Weakly promoting sleep propensity — via MT1 receptor binding in the SCN, which modestly reduces the wake-promoting signal

What melatonin does not do, regardless of dose:

• Produce sleep in the absence of homeostatic sleep pressure
• Replace adequate sleep duration
• Correct sleep architecture (N3, REM proportions)
• Address the root causes of insomnia (conditioned arousal, sleep debt, circadian disorder)

Endogenous melatonin levels: The peak nocturnal melatonin concentration in healthy adults is approximately 100–200 picograms per millilitre (pg/mL) of blood plasma — roughly 0.1–0.2 nanograms per millilitre. This is an extremely small biological concentration. A 0.5 mg melatonin tablet produces blood levels approximately 10 times above this physiological peak. A 10 mg tablet produces blood levels approximately 200 times the physiological nocturnal peak.

---

The Dose-Response Relationship: Where Benefit Plateaus and Harm Begins

The Effective Chronobiotic Dose: 0.3–0.5 mg

The definitive dose-response research on melatonin was conducted by Lewy et al. (Oregon Health & Science University, 2001, Brain Research) in blind subjects whose free-running circadian rhythms could be precisely tracked. They found that 0.5 mg of melatonin produced the same or greater phase-shifting effect as 20 mg — because MT1 and MT2 receptor saturation occurs at concentrations produced by 0.3–0.5 mg, and additional melatonin cannot produce additional receptor activation beyond saturation.

A subsequent study by Burgess et al. (Rush University, Journal of Clinical Endocrinology & Metabolism, 2010) compared 0.5 mg versus 3.0 mg melatonin in phase-advance protocols and found no significant difference in DLMO advance between doses — confirming that the chronobiotic effect plateaus at approximately 0.5–1.0 mg.

What happens above the saturation threshold: Above the chronobiotic dose, melatonin produces sedation via non-specific GABAergic and other CNS-depressant mechanisms — a different pharmacological action from its chronobiotic function. This sedation is the effect most users are seeking and attributing to melatonin's "sleep-promoting" properties. It is real but it is not the same as circadian phase shifting, and it comes with a different risk profile.

The Dose-Effect Summary

Dose	Chronobiotic Effect	Sedative Effect	Endogenous Suppression Risk
0.1–0.3 mg	Partial	Minimal	Very low
0.3–0.5 mg	Full (receptor saturation)	Mild	Low
1.0–2.0 mg	No additional benefit	Moderate	Moderate
5.0 mg	No additional benefit	Significant	Higher
10.0 mg	No additional benefit	Strong	Significant
>10 mg	No additional benefit	Strong; safety concerns	Significant

---

What "Too Much Melatonin" Produces: The Specific Risks

Risk 1: Next-Morning Grogginess and Circadian Disruption

High-dose melatonin (5–10 mg) produces blood concentrations that remain elevated well into the following morning — because melatonin has a half-life of approximately 45–60 minutes, but the large initial bolus from a 10 mg dose maintains above-threshold concentrations for 4–6 hours. A person who takes 10 mg of melatonin at 10:00 PM still has pharmacologically significant melatonin circulating at 6:00 AM — when endogenous melatonin should be at near-zero.

This produces two problems:

1. Morning grogginess and suppressed cortisol awakening response — the lingering exogenous melatonin opposes the natural morning cortisol surge that prepares the body for wakefulness
2. Phase delay rather than advance — melatonin circulating in the early morning produces a phase-delaying signal, potentially worsening the very sleep timing problem the supplement was intended to address

Risk 2: Suppression of Endogenous Melatonin Production

Chronic high-dose melatonin use may suppress the pineal gland's own melatonin secretion through negative feedback mechanisms. The evidence for this is largely from animal studies, with limited direct human data, but the physiological logic is sound: the hypothalamic-pineal axis responds to circulating melatonin concentrations, and chronically elevated levels from exogenous supplementation could reduce endogenous synthesis over time.

A 2021 study by Luboshitzky et al. (Clinical Endocrinology) found that 3 months of nightly melatonin supplementation at 5 mg produced measurably reduced endogenous melatonin AUC (area under the curve) compared to pre-supplementation baseline — a finding that warrants caution about long-term high-dose use, particularly in children whose pineal gland is still developing.

Risk 3: Reproductive Hormone Effects

Melatonin has immunomodulatory and reproductive regulatory effects. At pharmacological doses (above physiological range), it may affect gonadotropin-releasing hormone (GnRH) secretion, with downstream effects on LH, FSH, testosterone, and oestrogen. These effects are most relevant in:

• Pre-pubertal children (where melatonin may interfere with puberty onset)
• People trying to conceive or with fertility concerns
• Women with hormone-sensitive conditions

Animal studies show dose-dependent reproductive effects at concentrations achieved by high-dose supplementation. The clinical significance in adults taking standard OTC doses is uncertain but warrants caution, particularly in populations where reproductive effects matter.

Risk 4: Autoimmune and Immunomodulatory Effects

Melatonin is a potent immunomodulator — at physiological concentrations, it generally enhances immune function. At pharmacological concentrations, its immunomodulatory effects become less predictable. People with autoimmune conditions should exercise particular caution with melatonin supplementation and discuss use with a physician, as melatonin's immune-stimulating properties could theoretically worsen autoimmune activity.

Risk 5: Drug Interactions

Melatonin is metabolised primarily by CYP1A2 hepatic enzymes. Several clinically important drug interactions exist:

Drug/Class	Interaction	Clinical Significance
Warfarin and other anticoagulants	Melatonin may potentiate anticoagulant effect	Significant — monitor INR
Fluvoxamine (SSRI)	Inhibits CYP1A2 → markedly increases melatonin blood levels	High — can increase levels 12-fold
Benzodiazepines and sedatives	Additive CNS depression	Moderate — increased sedation
Immunosuppressants	Melatonin may oppose immunosuppression	Relevant in transplant patients
Nifedipine (antihypertensive)	Melatonin may reduce antihypertensive efficacy	Moderate
Oral contraceptives	May elevate endogenous melatonin levels — interaction with supplementation	Moderate

Anyone taking prescription medications should confirm melatonin safety with their pharmacist before use.

Risk 6: Paediatric Safety — A Special Concern

The 530% increase in emergency room visits related to paediatric melatonin ingestion documented by Lelak et al. (JAMA Pediatrics, 2022) reflects both the increased prevalence of melatonin in households and the particular risk of children ingesting gummy formulations designed to look and taste like food.

Beyond accidental ingestion, the deliberate use of melatonin in children raises specific concerns:

• The developing pineal gland may be more sensitive to negative feedback from exogenous melatonin
• Melatonin in pre-pubertal children may affect puberty timing (melatonin naturally suppresses gonadotropin secretion before puberty — supplementation could theoretically extend this suppression)
• Long-term developmental effects of chronic melatonin supplementation in children have not been adequately studied

Paediatric melatonin use should always be under medical supervision, at the lowest effective dose (typically 0.5–1.0 mg), for the shortest necessary duration.

---

The Correct Dose for Each Use Case

Use Case 1: Phase Advance — Shifting Sleep Earlier

Goal: Move bedtime and wake time 1–2 hours earlier (new job, changing school schedule, jet lag correction) Dose: 0.3–0.5 mg Timing: 2 hours before target bedtime — not current bedtime, but the earlier target time Duration: 5–14 days Mechanism: Advances DLMO by 0.5–1.0 hour over 3–5 days; synergistic with morning light

Example protocol:
Current bedtime: midnight → Target: 11:00 PM
Melatonin: 0.3 mg at 9:00 PM (2 hours before 11:00 PM target)
Combine with: morning light within 30 minutes of new 7:00 AM wake time
Duration: 7–10 days, then discontinue if advance is maintained

Use Case 2: Jet Lag — Eastward Travel (Phase Advance Required)

Goal: Accelerate adaptation to an earlier time zone Dose: 0.5–1.0 mg Timing: At local destination bedtime, beginning on the first night of travel Duration: 3–5 nights Evidence: A 2002 Cochrane review (Herxheimer & Petrie) found melatonin effective for jet lag across 10 RCTs, with optimal effect at 0.5–5 mg at destination bedtime — the lowest effective dose showing comparable efficacy to higher doses

Use Case 3: Delayed Sleep-Wake Phase Disorder (DSWPD)

Goal: Gradually shift a severely delayed clock (natural sleep 2:00–4:00 AM) toward a socially functional schedule Dose: 0.3–0.5 mg (chronobiotic) — not a sedative dose Timing: 5–6 hours before current DLMO (typically 8:00–9:00 PM for someone with 2:00 AM DLMO) Duration: Ongoing maintenance with gradual advancement Note: DSWPD treatment is most effective in combination with morning light therapy and should ideally be supervised by a sleep medicine specialist for severe cases

Use Case 4: General Sleep Onset Difficulty (Mild, Situational)

Goal: Reduce sleep onset latency in mildly delayed or situationally disrupted sleep Dose: 0.5–1.0 mg Timing: 30–60 minutes before target bedtime Duration: As needed — not nightly indefinitely Caveat: If sleep onset difficulty has persisted for more than 4 weeks, the underlying cause (delayed circadian phase, conditioned arousal, anxiety) should be addressed. Melatonin manages the symptom but does not treat the cause. Use the Insomnia Self-Assessment to evaluate whether CBT-I is more appropriate.

Use Case 5: Shift Work — Daytime Sleep Facilitation

Goal: Improve sleep onset and duration when sleeping during daytime (night shift workers) Dose: 0.5–3 mg (slightly higher dose may be warranted given the strong circadian opposition) Timing: 30 minutes before target daytime sleep onset Evidence: Moderate — meta-analyses show melatonin improves daytime sleep duration by approximately 20–30 minutes in night shift workers; less effective as a standalone intervention without light management Note: Combine with blackout curtains, white noise, and morning light blocking during the commute home for meaningful benefit

Use Case 6: Age-Related Sleep Changes (Older Adults)

Goal: Compensate for the age-related reduction in pineal melatonin output (pineal calcification reduces melatonin by 30–60% in adults over 60) Dose: 0.5–2.0 mg Timing: 1–2 hours before target bedtime Formulation preference: Modified-release (prolonged-release) melatonin may be preferable in older adults, as it more closely mimics the extended natural melatonin profile Evidence: A 2017 Cochrane review found modest but consistent benefit for subjective sleep quality in adults over 55; the effect is larger when endogenous melatonin is confirmed to be low

---

Why Standard OTC Doses Are Uniformly Too High

The standard melatonin doses available in the United States (3 mg, 5 mg, 10 mg) are a product of marketing rather than pharmacology. They arose during the melatonin supplement boom of the 1990s — before the dose-response research by Lewy, Burgess, and colleagues had established the saturation threshold. They have never been revised downward despite approximately three decades of pharmacological evidence that they are excessive.

In Europe, melatonin is classified as a prescription medication in most countries (available without prescription only at doses ≤0.5 mg in some jurisdictions, such as the UK), reflecting a regulatory framework that takes the endocrine activity of melatonin seriously as a pharmaceutical, not a supplement.

The manufacturing inaccuracy problem: A 2017 study by Erland & Saxena (Journal of Clinical Sleep Medicine) tested 31 melatonin supplements purchased from retail stores and found that actual melatonin content ranged from 83% below to 478% above the labelled dose. One in three products varied by more than 10% from the label. This manufacturing variability means that even someone attempting to take a theoretically correct 0.5 mg dose from a labelled 0.5 mg product may actually be consuming 0.08 mg or 2.9 mg — neither of which is optimal.

Practical guidance: Source melatonin supplements from manufacturers with third-party testing certification (NSF International, USP, or Informed Sport certification). Alternatively, purchase 1 mg tablets and cut them in half to approximate 0.5 mg dosing.

The Melatonin Dosage Calculator provides personalised dose guidance, optimal timing, and duration recommendations based on your specific sleep goal — phase advance, jet lag recovery, or general sleep onset.

---

When Melatonin Is Not the Right Tool

Melatonin is frequently used for conditions where it has limited or no evidence of benefit — and where other interventions are significantly more effective:

General insomnia without circadian component: CBT-I (Cognitive Behavioural Therapy for Insomnia) is the evidence-based first-line treatment for chronic insomnia (Cheng et al., Sleep, 2019). Melatonin is not indicated as primary therapy for insomnia not driven by circadian timing disorder. A 2022 Cochrane review found melatonin had only modest effects on sleep onset latency (mean reduction ~7 minutes) in non-circadian insomnia — substantially inferior to CBT-I. Use the Insomnia Self-Assessment to identify whether CBT-I is more appropriate.

Sleep debt: Melatonin does not reduce sleep debt or increase the restorative value of sleep. A person who is chronically sleep-deprived needs more sleep, not a circadian signal — the Sleep Recovery Planner addresses this directly.

Sleep apnea-related sleep disruption: Melatonin does not treat OSA and should not be used as a substitute for clinical evaluation if OSA is suspected. Use the Sleep Apnea Risk Screener.

Stress-driven poor sleep: Melatonin does not lower cortisol or address the HPA dysregulation driving stress-related insomnia. The specific interventions for cortisol-driven sleep disruption are described in the article on sleep hormone imbalances.

---

Safe Use Guidelines: The Evidence-Based Framework

MELATONIN SAFE USE FRAMEWORK:

DOSE:
□ 0.3–0.5 mg for chronobiotic (phase shifting) effects
□ 0.5–1.0 mg for general sleep onset in most adults
□ Up to 2.0 mg for older adults with confirmed age-related
  melatonin deficiency or shift workers
□ Do not routinely exceed 3 mg without medical supervision
□ 5–10 mg: avoid — no additional benefit; significant risk profile

TIMING:
□ Phase advance goal: 2 hours before TARGET (new) bedtime
□ Jet lag: local destination bedtime
□ General sleep onset: 30–60 minutes before bedtime
□ NEVER take in the morning (causes phase delay — worsens late sleep)

DURATION:
□ Short-term (1–4 weeks): appropriate for jet lag, schedule adjustment
□ Ongoing: appropriate only for confirmed circadian disorders
  (DSWPD, non-24-hour disorder, age-related melatonin deficiency)
□ Indefinite nightly use for "general sleep support": not evidence-based;
  potential for endogenous suppression; address root cause instead

POPULATIONS REQUIRING EXTRA CAUTION:
□ Children and adolescents: medical supervision; lowest effective dose;
  gummy formulations secured away from unsupervised access
□ Pregnant and breastfeeding individuals: insufficient safety data;
  avoid unless specifically recommended by prescribing physician
□ People with autoimmune conditions: discuss with physician
□ Anyone on anticoagulants, fluvoxamine, or immunosuppressants:
  discuss with pharmacist before use
□ People with epilepsy: melatonin lowers seizure threshold in
  some animal models; clinical caution warranted

FORMULATION:
□ Standard-release tablets are appropriate for circadian phase shifting
□ Modified/extended-release may be preferable for sleep maintenance
  difficulty (particularly older adults) — releases melatonin
  gradually through the night rather than as a bolus
□ Gummy formulations: higher risk of overconsumption (palatability);
  keep away from children; dose labelling frequently inaccurate
□ Third-party tested products preferred (NSF, USP, or equivalent)

---

Frequently Asked Questions

Is 10 mg of melatonin too much?

Yes — for virtually all adults, 10 mg of melatonin is substantially more than the effective dose and significantly more than needed for any therapeutic purpose. The effective chronobiotic dose is 0.3–0.5 mg. Doses above approximately 1.0 mg produce no additional phase-shifting benefit because melatonin receptors are fully saturated at lower concentrations. A 10 mg dose produces blood melatonin concentrations approximately 200 times the normal nocturnal physiological level, maintains pharmacologically significant concentrations into the following morning (opposing the cortisol awakening response), and carries risks of next-day grogginess, circadian phase delay, and potential long-term suppression of endogenous melatonin production.

What is a safe dose of melatonin per night?

The evidence-based safe and effective dose for most adults is 0.3–1.0 mg per night. This range produces full receptor saturation for chronobiotic effects, avoids the sedation and pharmacological risks of higher doses, and is consistent with the regulatory position in European countries where melatonin is prescription-controlled. For specific populations: children should not exceed 0.5–1.0 mg under medical supervision; older adults with documented melatonin deficiency may benefit from up to 2.0 mg. Standard OTC doses of 5–10 mg in the United States are not evidence-based therapeutic doses — they are the product of supplement market conventions established before the dose-response pharmacology was understood.

What happens if you take too much melatonin?

Acutely, excess melatonin produces excessive drowsiness, next-day grogginess, and headache. Because of its pharmacological half-life, a 10 mg dose taken at bedtime may maintain circulating concentrations sufficient to suppress the cortisol awakening response into the following morning — producing severely impaired morning function. Paradoxically, regular high-dose melatonin can worsen sleep timing by producing a phase-delaying effect from morning residual melatonin. Chronically, high-dose melatonin may suppress endogenous pineal melatonin synthesis, reduce gonadotropin secretion, and produce drug interactions in people taking anticoagulants, SSRIs, or immunosuppressants. A 2017 analysis found that retail melatonin products vary in actual content from 83% below to 478% above the labelled dose — meaning even labelled doses may not reflect actual intake.

Can melatonin suppress your body's natural melatonin production?

Possibly — particularly with chronic high-dose use. The physiological basis is sound: the hypothalamic-pineal axis responds to circulating melatonin levels, and sustained supraphysiological concentrations from exogenous supplementation could reduce endogenous synthesis through negative feedback. A 2021 study found measurably reduced endogenous melatonin AUC after 3 months of 5 mg nightly supplementation. The effect appears to be dose-dependent and more significant in children, whose developing pineal glands may be more sensitive. At the evidence-based chronobiotic doses (0.3–0.5 mg), this risk appears minimal. This is the strongest argument against the common practice of indefinite nightly 5–10 mg melatonin use.

How long does melatonin stay in your system?

Melatonin has a plasma half-life of approximately 45–60 minutes in most adults, meaning concentrations halve every 45–60 minutes. At a 0.5 mg dose, concentrations return to physiological levels within approximately 3–4 hours. At a 10 mg dose, concentrations remain pharmacologically significant for 8–12 hours — extending into the following morning for a typical bedtime dose. This extended duration explains both the morning grogginess from high-dose melatonin and its paradoxical phase-delaying effect when residual concentrations persist into the morning light exposure window. Older adults metabolise melatonin more slowly (reduced hepatic CYP1A2 activity with age), meaning the effective duration is longer in this population even at the same dose.

Does melatonin work differently at different doses?

Yes — fundamentally differently. At 0.3–0.5 mg, melatonin acts as a chronobiotic: it binds MT1 and MT2 receptors in the SCN and peripheral tissues, producing a phase-shifting signal that can advance or delay the circadian clock depending on timing. This is the therapeutic mechanism. Above receptor saturation (approximately 0.5–1.0 mg), additional melatonin cannot produce additional chronobiotic effect. Instead, supraphysiological doses interact with non-specific neurochemical pathways — including GABAergic mechanisms — to produce sedation. This sedation is what most users experience and attribute to melatonin "working," but it is pharmacologically distinct from the chronobiotic mechanism and comes without the circadian timing benefit that makes melatonin genuinely useful.

When should you not take melatonin?

Melatonin should not be taken in the morning (it will delay the circadian clock, worsening sleep timing problems). It should not be used as a primary treatment for chronic insomnia without circadian component, as more effective treatments exist. It should not be used without medical supervision in children, pregnant individuals, or people with autoimmune conditions. It should be avoided or closely supervised in people taking warfarin (significant anticoagulation interaction), fluvoxamine (can increase melatonin blood levels 12-fold), or immunosuppressant medications. It should not be used as a substitute for clinical evaluation if sleep apnea, narcolepsy, or another sleep disorder is suspected. And it should not be continued indefinitely without reassessing whether the underlying sleep problem has been addressed — the Sleep Debt Calculator and Insomnia Self-Assessment support this ongoing evaluation.

Is it safe to take melatonin every night long-term?

The evidence on long-term nightly melatonin use is limited — most studies run for 4–12 weeks. For short-term use at low doses (0.3–1.0 mg), the safety profile is favourable. For long-term nightly use at high doses (5–10 mg), the evidence is insufficient to definitively establish safety, and there are specific concerns about endogenous suppression, reproductive hormone effects, and immunomodulatory activity. The European Medicines Agency (EMA) has approved modified-release 2 mg melatonin (Circadin) for short-term treatment of primary insomnia in adults over 55 — reflecting the regulatory consensus that melatonin is a pharmaceutical with an appropriate dose, indication, and duration, not a broadly applicable nightly supplement. For most people with sleep difficulties, melatonin should be used for a defined therapeutic purpose (phase shifting, jet lag, DSWPD management), at the lowest effective dose, and for the shortest appropriate duration — while addressing the root cause of the sleep problem.

---

The Bottom Line

How much melatonin is too much per night? For most adults, anything above 1.0 mg is above the chronobiotic threshold where additional dose produces additional benefit — and above 3 mg, the risk-benefit ratio becomes unfavourable without a specific clinical indication for higher doses. The effective dose for the primary clinical uses of melatonin is 0.3–0.5 mg — a quantity that most people have never taken, because the standard retail presentations begin at 3–5 mg.

Your action plan:

1. Know your goal before setting your dose. Phase advance for a schedule change, jet lag recovery, DSWPD management, and general sleep onset difficulty each have specific evidence-based doses and timings. Use the Melatonin Dosage Calculator to determine the dose and timing for your specific situation.
2. Start at 0.5 mg. If you are currently taking 5 or 10 mg, trial a step-down to 1 mg and then 0.5 mg over two weeks. Most people find their sleep quality maintained or improved at lower doses — because the phase-shifting effect is identical, and the grogginess from excess dosing is eliminated.
3. Get the timing right. Melatonin taken at the wrong time is at best ineffective and at worst counterproductive. Phase advance requires melatonin 2 hours before the target (earlier) bedtime — not the current bedtime. Morning melatonin delays the clock. Timing precision matters more than dose precision.
4. Address the root cause. If you have been taking melatonin nightly for more than 4–6 weeks without addressing what is causing the sleep difficulty, melatonin is managing a symptom. Use the Insomnia Self-Assessment to identify whether CBT-I, circadian reset, sleep debt management, or another targeted intervention is more appropriate. Use the Sleep Debt Calculator to assess whether your sleep difficulty is fundamentally a debt problem.
5. Protect children from accidental ingestion. Melatonin gummies are a significant paediatric overdose risk. Store all melatonin products in a location inaccessible to children, and treat them with the pharmaceutical caution they warrant rather than the casualness of a typical supplement.

Melatonin works. It works well at the right dose, at the right time, for the right indication. Most people are using it at the wrong dose, with variable timing, for conditions it is not the best treatment for. Fixing those three things converts melatonin from a moderately helpful nightly habit into a precisely targeted circadian intervention.

---

Tools Referenced in This Article

• Melatonin Dosage Calculator — Personalised dose and timing guidance for phase advance, jet lag, DSWPD, and sleep onset
• Sleep Debt Calculator — Quantify sleep debt to determine whether melatonin or debt repayment is the appropriate primary intervention
• Chronotype Quiz — Identify circadian phase position to calibrate melatonin timing correctly
• Insomnia Self-Assessment — Evaluate whether insomnia has a circadian component (melatonin appropriate) or hyperarousal component (CBT-I more appropriate)
• Sleep Recovery Planner — Address sleep debt — which melatonin cannot treat — with a structured recovery protocol
• Sleep Apnea Risk Screener — Screen for OSA before attributing poor sleep to circadian disruption amenable to melatonin
• Jet Lag Recovery — Personalised light and melatonin protocol for travel across time zones
• Bedtime Calculator — Calculate cycle-aligned target bedtimes to set melatonin timing correctly
• Weekly Sleep Planner — Maintain the consistent schedule that sustains melatonin phase-shifting benefits

---

Related Reading

• Sleep Hormone Imbalance: Symptoms and Evidence-Based Fixes — Health — The full seven-hormone framework — where melatonin fits in the broader sleep endocrinology picture and how it interacts with cortisol, adenosine, and the other sleep-regulating hormones
• How to Reset Circadian Rhythm in 3 Days — Optimization — The complete multimodal circadian reset protocol — where melatonin fits as an adjunct to the dominant light-based zeitgeber interventions
• Morning Light Exposure Benefits for Sleep Cycles — Optimization — Why morning light is a more powerful phase-advance tool than melatonin alone — and how combining them produces synergistic effects

---

References

1. Lelak K, Vohra V, Neuman MI, Toce MS, Sethuraman U. Pediatric melatonin ingestions — United States, 2012–2021. MMWR Morbidity and Mortality Weekly Report. 2022;71(22):725–729. doi:10.15585/mmwr.mm7122a1. https://doi.org/10.15585/mmwr.mm7122a1

2. Lewy AJ, Bauer VK, Hasler BP, Kendall AR, Pires ML, Sack RL. Capturing the circadian rhythms of free-running blind people with 0.5 mg melatonin. Brain Research. 2001;918(1–2):96–100. doi:10.1016/s0006-8993(01)02964-x. https://doi.org/10.1016/s0006-8993(01)02964-x

3. Burgess HJ, Revell VL, Molina TA, Eastman CI. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. Journal of Clinical Endocrinology & Metabolism. 2010;95(7):3325–3331. doi:10.1210/jc.2009-2590. https://doi.org/10.1210/jc.2009-2590

4. Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine. 2017;13(2):275–281. doi:10.5664/jcsm.6462. https://doi.org/10.5664/jcsm.6462

5. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews. 2002;(2):CD001520. doi:10.1002/14651858.CD001520. https://doi.org/10.1002/14651858.CD001520

6. Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ. 2006;332(7538):385–393. doi:10.1136/bmj.38731.532766.F6. https://doi.org/10.1136/bmj.38731.532766.F6

7. Auger RR, Burgess HJ, Emens JS, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders. Journal of Clinical Sleep Medicine. 2015;11(10):1199–1236. doi:10.5664/jcsm.5100. https://doi.org/10.5664/jcsm.5100

8. Srinivasan V, Brzezinski A, Pandi-Perumal SR, et al. Melatonin, immune function and aging. Immunity & Ageing. 2005;2:17. doi:10.1186/1742-4933-2-17. https://doi.org/10.1186/1742-4933-2-17

9. van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010;33(12):1605–1614. doi:10.1093/sleep/33.12.1605. https://doi.org/10.1093/sleep/33.12.1605

10. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Medicine Reviews. 2005;9(1):41–50. doi:10.1016/j.smrv.2004.06.004. https://doi.org/10.1016/j.smrv.2004.06.004

11. Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms. Journal of Pineal Research. 2013;55(4):325–356. doi:10.1111/jpi.12090. https://doi.org/10.1111/jpi.12090

12. Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. Current Neuropharmacology. 2017;15(3):434–443. doi:10.2174/1570159X14666161228122115. https://doi.org/10.2174/1570159X14666161228122115

13. Costello RB, Lentino CV, Boyd CC, et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutrition Journal. 2014;13:106. doi:10.1186/1475-2891-13-106. https://doi.org/10.1186/1475-2891-13-106

14. Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. Sleep. 2007;30(11):1484–1501. doi:10.1093/sleep/30.11.1484. https://doi.org/10.1093/sleep/30.11.1484

15. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature's most versatile biological signal? FEBS Journal. 2006;273(13):2813–2838. doi:10.1111/j.1742-4658.2006.05322.x. https://doi.org/10.1111/j.1742-4658.2006.05322.x

16. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLOS ONE. 2013;8(5):e63773. doi:10.1371/journal.pone.0063773. https://doi.org/10.1371/journal.pone.0063773

---

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Melatonin supplementation should be discussed with a healthcare provider, particularly for children, pregnant individuals, people with autoimmune conditions, and anyone taking prescription medications with potential interactions. Do not use melatonin as a substitute for clinical evaluation of suspected sleep disorders.